A phase II study of panitumumab plus irinotecan for metastatic colorectal cancer with wild KRAS exon 2, resistant to fluoropyrimidine, oxaliplatin, and irinotecan in Japanese. Osaka Gastrointestinal cancer chemotherapy Study Group:（OGSG1001）

Taishi Hata, Motoki Yoshida, Koichi Taira, Naotoshi Sugimoto, Yukihiko Tokunaga, Takayuki Kii, Shin Kuwakado, Mutsumi Fukunaga, Hiroko Hasegawa, Takeshi Kato, Yasuhiro Miyake, Koji Takeda, Tetsuhiro Yoshinami, Haruko Daga, Daisuke Sakai, Toshio Shimokawa, Yukinori Kurokawa, Taro Sato, Toshimasa Tsujinaka, Hiroshi Furukawa ESMO-GI 2014, Barcelona, Spain, 25-28 Jun 2014

Warning: Trying to access array offset on false in /home/grwdev/grwdev.works/public_html/ogsg2026.grwdev.works/wp/wp-content/themes/OGSG/single.php on line 62